Thammathiwat T, et al. - Among multidrug-resistance (MDR) (n = 42) septic patients [with normal serum creatinine] receiving colistimethate sodium (CMS), researchers focused on the incidence as well as clinical results of clinical and subclinical acute kidney injury (AKI). Findings revealed an extremely high incidence of subclinical AKI in MDR septic patients prior to CMS treatment. For predicting clinical AKI, the best tool was baseline urinary liver-type fatty-acid-binding protein. The persistence of sepsis process, subclinical AKI and CMS nephrotoxicity were suggested as the possible causes of clinical AKI. In order to avert further renal impairment and enhance patient and renal outcomes, suitable management of subclinical AKI patients prior to CMS start should be concerned.